HREC Approval to Extend Phase II/III ASD Trial to Adults
Filed with ASX · · 2 pages · English
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- Neurotech Receives $3.17 Million R&D Tax Incentive Refund
- Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
- Completion of Patient Recruitment in NTIRTT1 Clinical Trial
- Last Patient Completes Treatment in NTIPANS1 Clinical Trial
- Appendix 4E & Annual Report
Later from Neurotech International
- Phase II/III Autism Clinical Trial Completes Recruitment
- NTI Receives HREC Approval for Cerebral Palsy Trial
- Neurotech Receives Additional HREC Approval in Autism
- PANDAS/PANS Patients Show Continued Clinical Improvement
- Rett Syndrome Patients to Receive NTI164 for 52 Weeks
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International